B. Lakshitha A. Perera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
B. Lakshitha A. Perera has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Eric R. Gamazon
Vanderbilt University Medical Center
2 shared publications - Sibo Lin
Department of Chemistry , Massachusetts Institute of Technology , Cambridge , Massachusetts 02139 , United States
2 shared publications Alexander G. Demidov
1 shared publication- Alexander G. Demidov
Department of Chemistry, George and Josephine Butler Polymer Research Laboratory, and Center for Macromolecular Science and Engineering, University of Florida
1 shared publication - Andrew S. Perry
Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center , Nashville, TN
1 shared publication Angela R. Grochowsky
Department of Pediatrics, Division of Medical Genetics and Genomic Medicine Vanderbilt University Medical Center Nashville Tennessee USA
1 shared publication
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (6) , e324171
Proteogenomic Analysis of Coronary Artery Calcification in Human Populations
BACKGROUND: Joint use of multiple molecular layers can be useful to prioritize targets for mechanistic studies. Application of this approach to coronary disease in large populations is an emerging field. METHODS: We used reported circulating proteomic data (Somascan aptamer-based) from ≈3000 individuals in the CARDIA study (Coronary Artery Risk Development in Young Adults), measuring association with prevalent and 10-year incident coronary artery calcium (CAC) score. We used a multiparametric approach to prioritize circulating protein-CAC associations via genomics of circulating protein levels and coronary artery transcription. RESULTS: Proteins linked to prevalent/incident CAC in CARDIA implicated pathogenic mechanisms of vascular disease, including fibrosis and inflammation (GDF-15 [growth/differentiation factor 15], CDCP1 [CUB domain–containing protein 1], GSN [gelsolin], THBS2 [thrombospondin-2], chemokines, RNAS6 [ribonuclease K6]), oxidative lipid metabolism (CILP2; cartilage intermediate layer protein 2), extracellular matrix remodeling and signaling (MMPs [matrix metalloproteinases], TIMP-1 [tissue inhibitor of metalloproteinases 1], integrins), calcification (Notch 1, ARHGAP36 [Rho GTPase-activating protein 36]), and metabolism (GIP [gastric inhibitory polypeptide]), as well as new proteins not previously reported. Using proteome-wide association study genetic approaches, several targets with nominal evidence in CAC proteomics were associated with atherosclerosis or myocardial infarction in over 300K individuals, including PCSK9 (proprotein convertase subtilisin/kexin type 9) and APOC1. Finally, the coronary artery–specific transcriptome-wide association study of CAC yielded genes with previously implicated mechanistic roles in vascular homeostasis, inflammation, and metabolism, as well as genes without previously described function in CAC. Overlap across CAC proteomics and transcriptome-wide association study highlighted genes involved in vascular inflammation (S100A9), cardiac development (HES1 [transcription factor HES-1]), vessel wall structure (SPARCL1 [SPARC-like protein 1]), and vascular dysfunction or plaque (NOTCH3 [neurogenic locus notch homolog protein 3], TNFSF12 [tumor necrosis factor ligand superfamily member 12], S100A12 [protein S100-A12]). CONCLUSIONS: These results report population-level multiomics in human coronary calcification, presenting a method to identify disease-relevant targets through integration of human genetic approaches with multiomics.
- 1 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (6) , e324171
Proteogenomic Analysis of Coronary Artery Calcification in Human Populations
BACKGROUND: Joint use of multiple molecular layers can be useful to prioritize targets for mechanistic studies. Application of this approach to coronary disease in large populations is an emerging field. METHODS: We used reported circulating proteomic data (Somascan aptamer-based) from ≈3000 individuals in the CARDIA study (Coronary Artery Risk Development in Young Adults), measuring association with prevalent and 10-year incident coronary artery calcium (CAC) score. We used a multiparametric approach to prioritize circulating protein-CAC associations via genomics of circulating protein levels and coronary artery transcription. RESULTS: Proteins linked to prevalent/incident CAC in CARDIA implicated pathogenic mechanisms of vascular disease, including fibrosis and inflammation (GDF-15 [growth/differentiation factor 15], CDCP1 [CUB domain–containing protein 1], GSN [gelsolin], THBS2 [thrombospondin-2], chemokines, RNAS6 [ribonuclease K6]), oxidative lipid metabolism (CILP2; cartilage intermediate layer protein 2), extracellular matrix remodeling and signaling (MMPs [matrix metalloproteinases], TIMP-1 [tissue inhibitor of metalloproteinases 1], integrins), calcification (Notch 1, ARHGAP36 [Rho GTPase-activating protein 36]), and metabolism (GIP [gastric inhibitory polypeptide]), as well as new proteins not previously reported. Using proteome-wide association study genetic approaches, several targets with nominal evidence in CAC proteomics were associated with atherosclerosis or myocardial infarction in over 300K individuals, including PCSK9 (proprotein convertase subtilisin/kexin type 9) and APOC1. Finally, the coronary artery–specific transcriptome-wide association study of CAC yielded genes with previously implicated mechanistic roles in vascular homeostasis, inflammation, and metabolism, as well as genes without previously described function in CAC. Overlap across CAC proteomics and transcriptome-wide association study highlighted genes involved in vascular inflammation (S100A9), cardiac development (HES1 [transcription factor HES-1]), vessel wall structure (SPARCL1 [SPARC-like protein 1]), and vascular dysfunction or plaque (NOTCH3 [neurogenic locus notch homolog protein 3], TNFSF12 [tumor necrosis factor ligand superfamily member 12], S100A12 [protein S100-A12]). CONCLUSIONS: These results report population-level multiomics in human coronary calcification, presenting a method to identify disease-relevant targets through integration of human genetic approaches with multiomics.
- Open Access
- 27 April 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (9) , 2140-2150
Response of an Infant With Presumed Multiple Acyl‐ CoA Dehydrogenase Deficiency ( MADD ) to Ketone Supplementation
Multiple Acyl‐CoA Dehydrogenase Deficiency (MADD) is an autosomal recessive inborn error of metabolism caused by biallelic pathogenic variants in one of three known genes: ETFA , ETFB , and ETFDH . It can cause multisystem dysfunction, including cardiomyopathy in severe cases. Ketone supplementation has been reported to be beneficial in a few case reports, but its long‐term effectiveness remains unclear. We report an infant with a clinical and biochemical diagnosis of MADD who showed a favorable response to ketone supplementation, with marked improvement in severe cardiac dysfunction and sustained near‐normal cardiac function and biochemical profiles over 3.5 years. Although genome sequencing did not identify causative variants, RNA sequencing revealed reduced ETFB transcript levels, and western blot analysis showed decreased ETFB protein levels. This case report illustrates MADD without an identified molecular diagnosis and provides evidence that near‐absent ETFB expression is likely responsible for his presentation. These observations can guide further studies investigating the transcriptional regulation of ETFB , thereby elucidating an underappreciated molecular mechanism underlying MADD. Initiating metabolic therapy in patients with clinically suspected MADD, even in the absence of a confirmed molecular diagnosis, can be beneficial as suggested by the clinical and biochemical responses to our therapeutic trial.
- 27 April 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (9) , 2140-2150
Open AccessResponse of an Infant With Presumed Multiple Acyl‐ CoA Dehydrogenase Deficiency ( MADD ) to Ketone Supplementation
Multiple Acyl‐CoA Dehydrogenase Deficiency (MADD) is an autosomal recessive inborn error of metabolism caused by biallelic pathogenic variants in one of three known genes: ETFA , ETFB , and ETFDH . It can cause multisystem dysfunction, including cardiomyopathy in severe cases. Ketone supplementation has been reported to be beneficial in a few case reports, but its long‐term effectiveness remains unclear. We report an infant with a clinical and biochemical diagnosis of MADD who showed a favorable response to ketone supplementation, with marked improvement in severe cardiac dysfunction and sustained near‐normal cardiac function and biochemical profiles over 3.5 years. Although genome sequencing did not identify causative variants, RNA sequencing revealed reduced ETFB transcript levels, and western blot analysis showed decreased ETFB protein levels. This case report illustrates MADD without an identified molecular diagnosis and provides evidence that near‐absent ETFB expression is likely responsible for his presentation. These observations can guide further studies investigating the transcriptional regulation of ETFB , thereby elucidating an underappreciated molecular mechanism underlying MADD. Initiating metabolic therapy in patients with clinically suspected MADD, even in the absence of a confirmed molecular diagnosis, can be beneficial as suggested by the clinical and biochemical responses to our therapeutic trial.
- Open Access
- 22 August 2022
- Published by University of Colorado at Boulder in Living Journal of Computational Molecular Science
- Vol. 4 (1) , 1561
Introduction to In Silico Synthesis of Polymers via PySIMM [Article v1.0]
Pysimm is a framework for molecular simulations of polymers and polymer-based nanostructures, which enables their direct chemical synthesis and preparation. Pysimm facilitates the understanding of novel, amorphous, processable materials for a broad range of applications, including heterogeneous catalysts, adsorbents and gas storage materials, as well as protein-polymer conjugates. This tutorial provides a detailed guide on the construction of atomistic and united-atom models of polymers using Pysimm: an open-source Python Application Programming Interface for atomistic molecular simulations. The API complements and simplifies the work of widely known molecular simulation software, such as LAMMPS, CASSANDRA, NAMD and Amber. Readers should be familiar with the basic concepts of atomistic molecular simulations, as well as the basic knowledge of Python programming language, before attempting to follow this tutorial. This work is separated into 3 main sections. First, the process of building an atomic-level model of a polymer chain from its repetitive units is described. The second section shows how to work with existing forcefields, and how Pysimm can automatically read, recognize, and assign appropriate Force Field parameters to a molecule. The final section discusses how to use Pysimm to construct polymer chains with pre-specified tacticity. The section is also available in the form of an interactive Jupyter notebook tutorial outlining simple guidelines to construct polymer models.
- 22 August 2022
- Published by University of Colorado at Boulder in Living Journal of Computational Molecular Science
- Vol. 4 (1) , 1561
Open AccessIntroduction to In Silico Synthesis of Polymers via PySIMM [Article v1.0]
Pysimm is a framework for molecular simulations of polymers and polymer-based nanostructures, which enables their direct chemical synthesis and preparation. Pysimm facilitates the understanding of novel, amorphous, processable materials for a broad range of applications, including heterogeneous catalysts, adsorbents and gas storage materials, as well as protein-polymer conjugates. This tutorial provides a detailed guide on the construction of atomistic and united-atom models of polymers using Pysimm: an open-source Python Application Programming Interface for atomistic molecular simulations. The API complements and simplifies the work of widely known molecular simulation software, such as LAMMPS, CASSANDRA, NAMD and Amber. Readers should be familiar with the basic concepts of atomistic molecular simulations, as well as the basic knowledge of Python programming language, before attempting to follow this tutorial. This work is separated into 3 main sections. First, the process of building an atomic-level model of a polymer chain from its repetitive units is described. The second section shows how to work with existing forcefields, and how Pysimm can automatically read, recognize, and assign appropriate Force Field parameters to a molecule. The final section discusses how to use Pysimm to construct polymer chains with pre-specified tacticity. The section is also available in the form of an interactive Jupyter notebook tutorial outlining simple guidelines to construct polymer models.